Further, the efficacy of the soluble Fzd7 has been taken into consideration and assessed thus far in two types of cancer, hepatocellular carcinoma (HCC) and triple breast cancer cells (TNBC) (14, 25). The gene discussed is FZD7; the disease is hepatocellular carcinoma.